Pay in 4 interest-free payments of $5.08 Learn more
Ships within 48 hours · Estimated delivery Aug 12 - Aug 17
What they found: Favorable safety profile , no serious adverse events at doses up to 100 g/kg Preliminary efficacy signals positive The program stopped before Phase 3 for unknown commercial reasons (the program passed through several sponsor rotations and no one ultimately carried it through) Why it matters: These are the only published clinical data in humans that we have
Explicit limitations bear repeating here
(a GLP-1 receptor agonist) enhances glucose-dependent insulin secretion
The volume of diluent used to reconstitute a lyophilised peptide determines the concentration of the resulting solution and, consequently, the volume required for each dose
US$ 25.89
US$ 20.21
US$ 29.58
US$ 22.56
